Celgene
NASDAQ: CELG
$108.24
+$0.00 (+0.0%)
Closing Price on November 22, 2019
CELG Articles
The three major U.S. stock indexes opened lower this morning after a weekend of mixed news from Asia. China’s trade balance rose on falling imports and industrial production failed to meet...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Monday. Advanced Micro Devices Inc. (NYSE: AMD) raised to Neutral from Sell at...
Published:
Last Updated:
The short interest in biotech stocks is generally rising, judging by the short interest changes from August 15 settlement date versus the July 31 settlement date. We have tracked the key short...
Published:
The short interest data is out from the July 31 settlement date and, with a couple of notable exceptions, short sellers generally have retreated from their gambles on biotech firms. For the period...
Published:
What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block. Monday’s...
Published:
Last Updated:
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech and emerging...
Published:
Last Updated:
Some wireless companies oppose the use of their networks as a means to make political contributions. (Reuters) Chinese inflation falls as the nation’s economy cools. (Reuters) The push to put...
Published:
GlobeImmune, Inc. is the latest biotech to file for an initial public offering. Financial terms were not disclosed but the first filing is for up to $69 million in common stock. This one has...
Published:
Last Updated:
The freshly announced multibillion biotech buyout of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) for more than $5 billion in equity value may be a bit misleading if you consider that it is...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Friday. Anthera Pharmaceuticals (NASDAQ: ANTH) Cut to Sell at Citigroup. Bed...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Friday. Celgene Corporation (NASDAQ: CELG) Maintained Buy with target of $73.00...
Published:
Last Updated:
While the Dow Jones Industrial Average, S&P 500 and NASDAQ are down slightly today after weak data on the U.S. labor market. Nevertheless, there are several big winners and losers as of...
Published:
Celgene Corporation (NASDAQ: CELG) is supposed to be one of the more promising biotechs out there. After all it was worth some $29.6 billion in market capitalization at Wednesday’s close. Now...
Published:
Last Updated:
The three major US stock indexes opened lower this morning as markets reacted to a rise in the yield of Spanish 10-year debt to more than 7% (our coverage here). The weekend elections in Greece...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Monday. Celgene Corporation (NASDAQ: CELG) Cut to Sector Perform at RBC. Cepheid...
Published:
Last Updated: